Summary of the current status of clinically diagnosed cases of Schnitzler syndrome in Japan.

[1]  C. Moltrasio,et al.  NLRP3 inflammasome and NLRP3-related autoinflammatory diseases: From cryopyrin function to targeted therapies , 2022, Frontiers in Immunology.

[2]  D. Lipsker,et al.  Absence of NLRP3 somatic mutations and VEXAS‐related UBA1 mutations in a large cohort of patients with Schnitzler syndrome , 2022, Allergy. European Journal of Allergy and Clinical Immunology.

[3]  T. Nomura,et al.  Refractory serum immunoglobulin M elevation during anti‐interleukin (IL)‐1‐ or IL‐6‐targeted treatment in four patients with Schnitzler syndrome , 2021, The Journal of dermatology.

[4]  K. Migita,et al.  A case of Schnitzler’s syndrome without monoclonal gammopathy successfully treated with canakinumab , 2021, BMC Musculoskeletal Disorders.

[5]  S. Roll,et al.  Tocilizumab treatment in patients with Schnitzler syndrome: An open-label study. , 2021, The journal of allergy and clinical immunology. In practice.

[6]  T. Nomura,et al.  Inducible skin‐associated lymphoid tissue (iSALT) in a patient with Schnitzler syndrome who manifested wheals on recurrent localized erythema , 2021, The British journal of dermatology.

[7]  M. Gertz.  Waldenström macroglobulinemia: 2021 update on diagnosis, risk stratification, and management , 2020, American journal of hematology.

[8]  D. Lipsker,et al.  Cytokine Signature in Schnitzler Syndrome: Proinflammatory Cytokine Production Associated to Th Suppression , 2020, Frontiers in Immunology.

[9]  T. Satoh,et al.  Schnitzler syndrome with basophil infiltration , 2020, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[10]  M. Furue,et al.  Schnitzler's syndrome: A female elderly case presenting intractable non-pruritic febrile urticarial rush. , 2020, Asian Pacific Journal of Allergy and Immunology.

[11]  J. Fischer,et al.  Long-term Efficacy of Canakinumab in the Treatment of Schnitzler Syndrome. , 2020, The Journal of allergy and clinical immunology.

[12]  O. Decaux,et al.  Diagnostic value of 18-F fluorodeoxyglucose PET/CT and bone scan in Schnitzler syndrome , 2019, Autoimmunity.

[13]  O. Ohara,et al.  Low-frequency mosaicism in cryopyrin-associated periodic fever syndrome: mosaicism in systemic autoinflammatory diseases. , 2019, International immunology.

[14]  Philip R. Cohen,et al.  Schnitzler syndrome associated with MYD88 L265P mutation , 2019, JAAD Case Reports.

[15]  H. Hoffman,et al.  CAPS and NLRP3 , 2019, Journal of Clinical Immunology.

[16]  Hirotoshi Tanaka,et al.  Role of the Glucocorticoid Receptor in Systemic Energy Metabolism , 2018, Nihon Naika Gakkai Zasshi.

[17]  M. Tokuda,et al.  A case of Schnitzler's syndrome with fever, rash and extremity pain , 2018 .

[18]  Baoxi Wang,et al.  A case of Schnitzler′s syndrome , 2017 .

[19]  J. Fischer,et al.  Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo‐controlled study , 2017, The Journal of allergy and clinical immunology.

[20]  Mikaël M. Martino,et al.  Inhibition of IL-1R1/MyD88 signalling promotes mesenchymal stem cell-driven tissue regeneration , 2016, Nature Communications.

[21]  O. Ohara,et al.  Somatic NLRP3 mosaicism in Muckle-Wells syndrome. A genetic mechanism shared by different phenotypes of cryopyrin-associated periodic syndromes. , 2015, Annals of the rheumatic diseases.

[22]  P. Jansen,et al.  Myeloid lineage-restricted somatic mosaicism of NLRP3 mutations in patients with variant Schnitzler syndrome. , 2015, The Journal of allergy and clinical immunology.

[23]  H. D. de Koning.  Schnitzler’s syndrome: lessons from 281 cases , 2014, Clinical and Translational Allergy.

[24]  B. Grosbois,et al.  Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler's syndrome: a French multicenter study. , 2014, Autoimmunity reviews.

[25]  Mayuko Yamamoto,et al.  Successful treatment of Schnitzler syndrome with cyclosporine , 2014, International journal of dermatology.

[26]  L. Schnitzler,et al.  Schnitzler's syndrome: diagnosis, treatment, and follow‐up , 2013, Allergy.

[27]  S. Akira,et al.  Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome , 2013, Nature Immunology.

[28]  Y. Iwafuchi,et al.  Schnitzler syndrome complicated by membranous nephropathy. , 2012, Clinical nephrology.

[29]  T. Zuberbier,et al.  Efficacy and safety of the interleukin‐1 antagonist rilonacept in Schnitzler syndrome: an open‐label study , 2012, Allergy.

[30]  D. Lipsker.  The Schnitzler syndrome , 2010, Orphanet journal of rare diseases.

[31]  K. Narushima,et al.  Schnitzler’s syndrome with prominent neutrophil infiltration misdiagnosed as Sweet’s syndrome: a typical example of urticarial neutrophilic dermatosis , 2010, Clinical and experimental dermatology.

[32]  I. Matsumura,et al.  Improvement of recurrent urticaria in a patient with Schnitzler syndrome associated with B-cell lymphoma with combination rituximab and radiotherapy. , 2009, Journal of the American Academy of Dermatology.

[33]  M. Itoh,et al.  Schnitzler's Syndrome with IgG κ Gammopathy , 2002 .

[34]  Y. Shirafuji,et al.  Schnitzler's syndrome versus adult onset Still's disease. , 1998, EJD. European journal of dermatology.

[35]  T. Tsuji,et al.  A Case of Urticarial Vasculitis Associated with Macroglobulinemia (Schnitzler's Syndrome) , 1995, The Journal of dermatology.

[36]  M. Pillinger,et al.  Update on colchicine, 2017 , 2018, Rheumatology.

[37]  Ryan M. O’Connell,et al.  MyD88 mediates neutrophil recruitment initiated by IL-1R but not TLR2 activation in immunity against Staphylococcus aureus. , 2006, Immunity.